Cargando…
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patients and to investigate the exposure–response relatio...
Autores principales: | Balakirouchenane, David, Guégan, Sarah, Csajka, Chantal, Jouinot, Anne, Heidelberger, Valentine, Puszkiel, Alicja, Zehou, Ouidad, Khoudour, Nihel, Courlet, Perrine, Kramkimel, Nora, Lheure, Coralie, Franck, Nathalie, Huillard, Olivier, Arrondeau, Jennifer, Vidal, Michel, Goldwasser, Francois, Maubec, Eve, Dupin, Nicolas, Aractingi, Selim, Guidi, Monia, Blanchet, Benoit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226106/ https://www.ncbi.nlm.nih.gov/pubmed/32283865 http://dx.doi.org/10.3390/cancers12040931 |
Ejemplares similares
-
Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022) -
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022) -
Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022) -
Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017) -
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
por: Velev, Maud, et al.
Publicado: (2021)